As part of our spotlight on formulation series, Maura McArdle and Audrey Vardy from Quay Pharma, share a discussion about Quay Pharma’s preclinical service and expertise in their recent podcast.
The podcast is the second in the QuayCast series, and provides a background to the services Quay Pharma offers. The podcast also talks about the solubility screen, which is carried out using a scientific and tailored approach; discussion where this sits in relation to animal studies and formulation development; the importance of involving a DMPK provider for initial PK studies; and how the services work for new chemical entities and new drug products as well as reformulations.
To listen to the podcast, click on the play button below:
Quay Pharma is one of XenoGesis’ carefully selected CDMO partners, as announced in a recent news story.
To find out more about formulation services from XenoGesis and its CDMO partners, click here.